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ABSTRACT 
 
Cardiovascular disease is the leading cause of death in Canada.  Despite 
improvements in cardiovascular risk factor identification and management over the past 
couple decades, many patients are still not reaching their guideline-recommended blood 
pressure, cholesterol, or blood glucose targets.  Although numerous studies have 
demonstrated benefits to incorporating pharmacists onto primary care teams to facilitate 
cardiovascular risk reduction, such initiatives are not currently being implemented on a 
widespread basis in Canada.  Part of the reason for this may be that most studies have 
been conducted in specialized, tertiary care clinics, while the majority of Canadians 
receive care from family physicians.   
CCARP II was a prospective, before and after clinical initiative implemented to 
help bridge this gap between clinical research and current clinical practice.  The purpose 
of CCARP II was to implement and evaluate a pharmacist-led collaboration to identify 
and manage cardiovascular risk factors in a real-world family medicine setting.   
The pharmacist screened 566 patients for uncontrolled cardiovascular risk factors 
over the 9-month study period.  Of all patients screened, 186 (32.9%) were at moderate or 
high cardiovascular risk with one or more risk factors above target.  Of those, 113 
patients (60.8%) were referred back to the pharmacist by their physician for ongoing 
monitoring and follow-up.  In this group of patients, statistically significant reductions in 
systolic blood pressure, LDL cholesterol, and the total cholesterol: HDL ratio were 
observed over the study period.  In patients started on new medications over the study 
period, a high rate of persistence (87.8%) was observed. 
 iii
CCARP II demonstrated that there is still a need for systematic screening for 
unidentified or uncontrolled cardiovascular risk factors in adult patients visiting their 
physicians; almost one-third of patients in our study had one or more uncontrolled risk 
factors identified.  This initial pilot project was successful in identifying patients with 
above-target cardiovascular risk factors, and subsequently aiding in the reduction of these 
risk factors towards target levels.   
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CHAPTER 1 
 
1. Literature Review 
1.1 Introduction 
 
Cardiovascular disease is the leading cause of death in Canada (1).  Despite 
improvements in risk factor identification and management over the past several 
decades, many people are still not reaching their blood pressure, cholesterol, and 
blood glucose targets (2-5).  Numerous studies have demonstrated benefits to 
incorporating pharmacists onto primary care teams to facilitate cardiovascular risk 
reduction (6-17); however, these interventions are not currently being implemented 
on a widespread basis (18-21).      
CCARP II was designed to help bridge this gap between clinical research 
and current clinical practice.  Most of the previous pharmacist interventions to 
reduce cardiovascular risk have taken place in specialty outpatient clinics, often 
affiliated with tertiary care hospitals (6-8,11,16,17,22-25); however, the majority of 
Canadians receive their care from family physicians (26). Thus, there is a need to 
determine whether a collaborative pharmacist-physician protocol designed to reduce 
cardiovascular risk would be feasible and effective in a real-world primary care 
family medicine setting.  The purpose of CCARP II is to implement and evaluate a 
pharmacist-led collaboration to identify and manage uncontrolled CV risk factors in 
a family medicine setting. 
 
1.2 Cardiovascular Disease in Canada 
 
Cardiovascular disease remains the leading cause of death and is the most 
costly disease in Canada despite declining mortality and hospitalization rates over 
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the last decade (1,27).  The cost of providing healthcare to patients with heart attacks 
and strokes, as well as the resulting lost productivity, has been estimated at $22 
billion annually or 12% of the national cost of illness (28,29).  As the population 
ages and the prevalence of cardiovascular disease (CVD) increases, these costs are 
expected to rise substantially (27,28).   
Epidemiologic studies suggest that the improvements in cardiovascular (CV) 
morbidity and mortality that have been made over the last decade may not be 
sustained.  The incidence of obesity and diabetes, which are major risk factors for 
CVD, has been increasing at an alarming rate in Canada.  Saskatchewan-specific 
data have shown that the age and sex-adjusted prevalence of diabetes increased 44% 
from 1993-2001 (30); more recent data from the National Diabetes Surveillance 
System has shown a 24% increase in the age and sex-adjusted prevalence of diabetes 
in Canada from 2000-2001 to 2004-2005 (31).  Nationally, the adjusted prevalence 
of hypertension has almost doubled from 8.4% to 14.6% between 1994 and 2005 
(32).  The increasing prevalence of hypertension, diabetes, and obesity is especially 
evident among younger adults (32,33), and this portends future increases in CVD 
unless aggressive preventive measures are instituted.  
 
1.2.1 Management of Cardiovascular Risk Factors 
 
Nine out of every 10 Canadians older than 20 years of age has at least one 
modifiable risk factor for CVD, and one-third of Canadians have three or more risk 
factors (including high blood pressure, diabetes, tobacco smoking, overweight or 
obesity, lack of physical activity, inadequate consumption of fruits and vegetables, 
and high or extreme stress) (28,31).  However, established medical therapies are 
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consistently under-utilized in patients with cardiovascular disease or its risk factors 
and the majority of patients are not reaching their cholesterol, blood pressure, and 
blood glucose goals (2).  Using data from two large, prospective Canadian 
databases, Hackam and colleagues showed that only 50% of patients with known 
cardiovascular disease had their LDL cholesterol or total-cholesterol to HDL-
cholesterol ratio at target (4).  A retrospective cohort study from Ontario found that 
63.2% of patients with dyslipidemia were untreated, and that women were less likely 
to be treated than men (5).  In terms of hypertension, the study by Hackam and 
colleagues reported that only 44% of hypertensive patients achieved their target 
systolic blood pressure (4), while a chart review of primary care patients in North 
Carolina showed that blood pressure was above target in 52.9% of patients and only 
44.3% of these patients had had therapy intensified in the past year (34).  Although 
results from a recent cross-sectional study in Ontario suggest that rates of 
hypertension control have improved significantly over the past decade, the overall 
rate of uncontrolled hypertension remains quite high at 34.3% (35).  Furthermore, 
among those patients with concurrent diabetes, uncontrolled hypertension was 
observed in the majority of patients examined (63.9%) (35).   Similar findings have 
been reported for blood glucose control amongst diabetic patients in Canada where 
only 64% achieved their fasting targets (3).    
Overall, only a small fraction of high risk patients in Canada (21%) appear to 
have all of their modifiable risk factors under control (3). For moderate risk patients, 
where the targets for CV control are less strict, the proportion of individuals with 
optimal control is better, but still far from ideal (66%) (3).  These data suggest that a 
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significant gap exists between guideline-recommended practices and current patient 
care.  
One possible explanation for the treatment gap regarding CV risk reduction 
targets is the use of inadequate doses of medications (4). One study found that only 
25-50% of the target doses of 3-hydroxy-3-methylglutaryl coenzyme A reductase 
inhibitors (statins) and angiotensin-converting enzyme inhibitors (ACEIs) used in 
clinical trials were prescribed to patients at high risk of cardiovascular events, 
despite low rates of patients reaching their cholesterol and blood pressure goals (4).  
It has also been shown that the likelihood that a patient with above-target blood 
pressure, blood glucose, or cholesterol levels will have drug therapy initiated or 
titrated at a routine physician office visit is less than 20% (4,36).  We believe that 
opportunities exist to close this treatment gap among patients with uncontrolled 
cardiovascular risk factors. 
 
1.3 Primary Care and Cardiovascular Disease 
 
Patients with CVD receive a large proportion of their care from family 
physicians (26).  A Nova Scotia study found that 95% of cardiovascular drug 
prescriptions for seniors are written by family physicians (37).  Also, an Ontario 
study found that 12% of all family physician office visits are for CVD or its risk 
factors (38).  Thus, family physician offices are clearly important settings for the 
care of patients with CVD.   
However, there are limitations to the provision of comprehensive 
cardiovascular care in family medicine settings.  The main issue cited for shortfalls 
in the treatment of cardiovascular risk factors was time constraints (34).  Healthy 
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patients generally do not book physician appointments, so physicians often must 
prioritize their time to acute issues rather than asymptomatic risk factor management 
(34,39).  Attempts are currently being made to address this; in Saskatchewan and 
other provinces, the government has implemented chronic disease management 
billing codes to facilitate guideline-recommended management of select chronic 
diseases by fee-for-service family physicians, including diabetes, coronary artery 
disease, and heart failure (40).  However, there are many patients with CVD risk 
factors who do not have pre-existing CAD, diabetes, or heart failure.  For example, 
approximately 63% of all coronary events occur in patients with no history of CAD 
(41).  The Saskatchewan Ministry of Health is also attempting to develop primary 
health care clinics across the province that pay physicians on a salary as opposed to 
the typical fee-for-service structure (42).  This alternate payment structure has been 
adopted to ensure that a physician’s income “does not suffer because they spend 
needed time with a client…” for chronic disease management activities (42).  To 
date, we know of no published study that definitively quantifies the impact of these 
initiatives.   
 
1.3.1 Pharmacists and Primary Care 
   
Clearly, there exists a treatment gap with respect to the optimal management 
of cardiovascular risk factors in Canada.  It has been proposed that the formation of 
primary care teams might minimize the care gaps that exist within the current 
healthcare system, specifically regarding health promotion and disease prevention 
(43).  As medication therapy plays a significant role in the management of CV 
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disease prevention and management, expanding the presence of pharmacists on 
primary care teams has been an area of interest for the past several years (18,43).   
However, pharmacists appear to be under-utilized and under-represented on 
primary care teams in Canada (18-21).  The slow uptake of pharmacists into these 
positions may be a result of several factors.  First, pharmacists themselves may not 
be ready to take on an expanded role.  A recent survey of practicing pharmacists in 
Canada found that, while the majority want to provide enhanced clinical services for 
patients, only 43.5% felt prepared to take on these advanced roles (44).  Pharmacists 
cite a lack of understanding regarding their role on primary care teams as a barrier to 
wanting to practice in this setting (20,45).  Similarly, it has been suggested that other 
healthcare professionals may be uncertain as to pharmacists’ roles on primary care 
teams (46).  Secondly, health system barriers such as lack of renumeration for 
clinical pharmacy services may also be a hindrance (47,48).  The majority of 
pharmacists practicing in Canada are paid through the dispensing fees associated 
with filling prescriptions in community pharmacy practice (47,49).  However, it 
would appear that there exists a great opportunity for pharmacists to facilitate CV 
risk reduction activities in primary care centres in Canada if such barriers can be 
overcome.       
 
1.3.2 Pharmacist Interventions to Improve Cardiovascular Risk Indicators in Primary 
Care 
 
There are numerous studies of pharmacist interventions to improve specific 
CVD risk factors, including blood pressure (50-52) and cholesterol levels (53-55).  
Additionally, a meta-analysis has found benefit to pharmacist interventions in 
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hypertension, dyslipidemia, and diabetes (56).  However, there are fewer examples 
of pharmacist programs targeting global CV risk reduction (Table 1.1).  Because 
cardiovascular risk factors tend to cluster within patients, and because they tend to 
have a synergistic impact on overall cardiovascular risk, addressing risk factors in 
isolation may be missing an important opportunity.  Of the studies that have reported 
benefits of pharmacists working collaboratively with physicians and other healthcare 
providers to address global CV risk in primary care (6-10,12-17,22,57), issues 
relating to internal and external validity hinder these studies from providing robust 
evidence for the optimal activities of a primary care pharmacist in this setting.  This 
is likely partially responsible for the currently limited utilization of clinical 
pharmacists in real-world primary care settings.   
The internal validity of available global CV risk reduction studies is 
frequently low.  Of the 21 studies described in Table 1.1, only six were randomized 
controlled trials (15,17,25,57-59).  One of these studies did not achieve their target 
patient recruitment, thus reducing their power to detect a difference between groups 
(58).  Two studies (6,10) randomly assigned patients to pharmacist intervention or 
usual care groups; however, no between-group comparisons were made, eliminating 
the benefit of the randomly assigned control group.   
In 2009, members of our research group conducted a randomized controlled 
trial examining a global CV risk reduction intervention within a family medicine 
practice in Saskatoon (59).  Although the study was designed to maximize internal 
validity, several questions remained unanswered at the completion of the trial.  First, 
physician referral of at-risk patients was slow throughout the trial period.  Thus, 
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would the identification of at-risk patients improve if the pharmacist was responsible 
for patient screening?  Secondly, data from a post-hoc analysis conducted after the 
study suggested that participating physicians were influenced by the Hawthorne 
effect because they were caring for patients in both the usual care groups and 
intervention groups simultaneously.  The Hawthorne effect is an alteration in a study 
participant’s behaviour or study outcomes due to the participant’s awareness that 
they are being observed (60).  Would the impact of the intervention have been more 
pronounced without this confounding influence?  Third, all patients in this trial were 
required to sign informed consent prior to enrolment, and only 70% of those referred 
were subsequently enrolled.  Would the ability of the pharmacist to facilitate CV 
risk improvement be different if applied to all patients within a clinic rather than just 
those volunteering for a study?  Fourth, the intervention was applied to all patients at 
high risk for CV disease, reducing our ability to detect an impact of the intervention 
for those patients that were already well controlled.  What would be the benefits if 
we restricted our intervention to those with uncontrolled risk factors only?  Finally, 
if the option of pharmacist prescribing was offered to physicians for the purposes of 
titrating medications to target, to what extent would they refer patients for this 
service?     
The majority of these questions were a result of the poor external validity of 
our study due to the strict requirements of the RCT study design.  Indeed, external 
validity of many published studies in this area is also quite low.  Many of the studies 
were conducted in specialized hospital or outpatient clinic settings (6-8,11,16,17,22-
25), while the majority of Canadian patients receive care from general family 
 9
medicine clinics (26).  It is likely that the practitioners who work in specialty 
practices are not representative of the doctors and pharmacists that work in family 
medicine settings.  One of the greatest barriers to collaboration in family physician 
practices is the time required for these initiatives (61).   
Many of the pharmacist interventions previously described in the literature 
involved time-intensive pharmacist interventions and had low sample sizes 
(23,24,62,63).  Considering the high volume of patients seen in family physician 
clinics along with the high prevalence of CV risk factors among Canadian adults, 
time-consuming pharmacist interventions that enrol small numbers of patients are 
likely inadequate to address the needs of this population.  Additionally, protocols 
relying on physician referral for patient recruitment (7,12,16,23,24,57,59) are 
limited by the potential for missing patients with unidentified CV risk factors.   
Previous CV risk reduction initiatives led by pharmacists have been varied in 
scope and focus of the intervention, making it difficult to ascertain which factors are 
associated with CV risk reduction success.  Many involved assessment and 
communication of patients’ CV risk (8,9,13,16,59).  Most of the interventions have 
involved patient education and counselling to some extent 
(6,7,10,12,14,16,17,22,59).  However, it is often difficult to determine the amount of 
time spent on these activities.  Additionally, most of the interventions have involved 
assessments of patients’ drug therapies, ongoing monitoring for target achievement, 
and recommended or implemented alterations to facilitate CV risk reduction (6,7,9-
17,22,57,59).     
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Collaborative prescribing agreements, which enable pharmacists to titrate 
and adjust select medications, have been used in several studies to facilitate CV risk 
reduction success (7,12,13,16,57).  It has been suggested that collaborative 
prescribing by pharmacists may produce greater improvements in clinical 
parameters than those in which the pharmacist makes recommendations to the 
physician (64,65).  Of the 17 studies reviewed here, five utilized collaborative 
prescribing agreements, and all found positive results of the pharmacist intervention 
(7,12,13,16,57).  Of the 12 studies that relied on pharmacists making 
recommendations for drug therapy changes to the physician, nine found a positive 
result of the pharmacist intervention (6,8-10,14,15,17,22), while three found no 
difference (25,58,59).  Thus, it is still unclear if pharmacist-prescribing protocols 
facilitate success to a greater extent.  In addition, the extent to which participating 
physicians would choose the option of pharmacist prescribing on a case-by-case 
basis has only been examined in one other study (7); it would be interesting to 
corroborate these findings.    
Many pharmacist intervention studies have been published over the past 
several years; however, a definitive conclusion about the role of pharmacists in CV 
risk reduction in primary care remains elusive.  Not all of the studies have been 
positive (25,58,59) and interventions have varied widely in terms of the focus and 
scope of the activities conducted by the pharmacist.  Also, the generalizability of 
many studies is limited due to their specialized practice setting (6-8,11,16,17,22-25).  
The majority of the studies relied on referrals for patient recruitment, potentially 
missing patients with unidentified CV risk factors (7,12,16,23,24,57,59).   
  
 
Table 1.1:  Summary of Pharmacist Interventions to Reduce Global Cardiovascular Risk 
Study Design Patients Intervention Outcomes 
MEDMAN (58) Randomized 
controlled trial 
n = 1493 patients 
with established 
CHD 
(Did not achieve 
target patient 
recruitment) 
Pharmacist assessment and follow-up; 
recommendations sent to family 
physician. 
No significant between- group 
differences in proportion of 
patients receiving appropriate 
treatment for CHD (per the 
National Service Framework). 
Simpson et al. 
(15) 
Randomized 
controlled trial 
n = 260 patients 
with T2DM 
Pharmacist assessment and follow-up; 
recommendations discussed with 
primary care physician. 
Primary Outcome: Intervention 
group had a significantly greater 
decrease in SBP (-7.4mmHg) 
than control group (-2.5mmHg) 
over 1 year (4.9mmHg difference 
in favor of the intervention; 
p=0.01).  Trend towards 
improved glycemic and lipid 
control, not statistically 
significant. 
Rothman et al. 
(57) 
Randomized 
controlled trial 
n = 217 patients 
with poorly 
controlled T2DM 
(A1c > 8%) 
Patient education, cardiovascular risk 
assessments, medication initiation and 
titration (per algorithms), ongoing 
monitoring and follow-up of clinical 
parameters versus one-time 
pharmacist education session 
followed by usual care. 
Intervention group had 
significantly lower systolic blood 
pressure (-9 mmHg) and A1c 
levels (-0.8%) compared to the 
usual care group.  In the 
intervention group, 91% of 
patients were on aspirin therapy 
versus 58% of control patients 
(p<0.001).  No significant 
between-group differences in 
total cholesterol levels were 
1
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Study Design Patients Intervention Outcomes 
observed. 
CCARP (59) Randomized 
controlled trial 
n = 176 patients in a 
large family 
medicine practice in 
Saskatoon, SK, with 
a Framingham risk 
score of > 15% or a 
CAD equivalent 
Pharmacist met with each patient to 
review medications, calculate their 
Framingham Risk Score, and provide 
patient education.  Patients were then 
randomly assigned to pharmacist 
follow-up or return to usual care.  
Pharmacist determined blood 
pressure, cholesterol, and blood 
glucose targets for patients in the 
intervention group, and notified the 
patient and the physician of risk 
factors not at target.  The pharmacist 
followed-up with patients in the 
intervention arm every eight weeks to 
assess target achievement, provide 
education and promote adherence. 
There was no significant 
difference in mean reductions in 
Framingham risk score between 
groups (-2.68 in the intervention 
and -1.25 in the single-contact 
group, p=0.098).  There were no 
significant between-group 
differences in BP, LDL-C, TC: 
HDL-C ratio, or A1c.  Statin 
utilization was significantly 
higher in the pharmacist follow-
up group (85.2% vs. 67%). 
VA-MEDIC 
(17) 
Randomized 
controlled trial 
n = 109 patients 
with uncontrolled 
diabetes 
Group education sessions by 
pharmacists, nurses, physical 
therapists and dietitians, followed by 
pharmacist intervention sessions. 
A significantly greater proportion 
of patients in the intervention 
group achieved their target A1c 
and BP levels compared to the 
usual care group; no significant 
between-group differences were 
seen in cholesterol levels or 
smoking rates. 
Phumipamorn 
et al. (25) 
Randomized 
controlled trial 
n = 135 Muslim 
patients with 
diabetes in Thailand 
Patient education, adherence 
assessments. 
No significant between-group 
differences in A1c before or after 
the intervention. Significant 
reductions in TC and LDL-C 
1
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Study Design Patients Intervention Outcomes 
were observed in the intervention 
group compared to the control 
group.  
Al Mazroui (6) Randomized 
before/after trial 
with concurrent 
control group 
n = 240 patients 
with T2DM in the 
United Arab 
Emirates 
Medication review, drug and disease-
state counselling, adherence support.  
Recommendations discussed with 
family doctor. 
Significant reduction in A1c in 
intervention group (from 8.5 to 
6.9%). Also reduced 
Framingham risk score, systolic, 
and diastolic blood pressure in 
the intervention group; no change 
in the control group from 
baseline. 
Freemantle 
Diabetes Study 
(10) 
Randomized 
before/after trial 
with concurrent 
control group 
n = 198 patients 
with diabetes in 
Australia 
Baseline, 6, and 12-month lifestyle 
and medication counselling as well as 
follow-ups every 6 weeks by a 
pharmacist. Recommendations sent to 
family physician. 
A1c was reduced by 0.5% from 
baseline in the intervention 
group; no change in the control 
group. Estimated 10-year risk of 
CV events (per UKPDS risk 
engine) decreased from 25.1 to 
20.3% in the intervention group, 
while no change was seen in the 
control group. 
Asheville 
Project (8) 
Before/ after 
study 
n = 565 patients 
employed by the 
City of Asheville or 
Mission Hospitals 
with hypertension 
or dyslipidemia 
Patient education, medication 
reviews, monitoring. 
Recommendations sent to family 
physician. 
Significant improvement in 
systolic BP post-intervention 
(137 to 126 mmHg). Proportion 
of patients achieving target BP 
improved from 40.2 to 67.4%. 
Significant reduction in LDL-C, 
TC, and TG; proportion of 
patients achieving LDL-C targets 
increased from 49.9 to 74.6%. 
1
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Taveira et al. 
(16) 
Retrospective 
cohort study 
(before/ after 
intervention) 
n = 355 patients at 
high-risk of CVD at 
a Veteran Affairs 
Medical Centre in 
the United States 
Pharmacists provided patient 
education, assessed patient adherence, 
monitored laboratory values, and 
developed a drug therapy regimen to 
achieve CV risk reduction targets 
using medication titration algorithms 
for hypertension, diabetes, 
cholesterol, and smoking cessation. 
10-year CV risk (as assessed by 
Framingham) decreased from 
16% to 12% post-intervention.  
TC, LDL-C, A1c, and SBP were 
all significantly reduced post-
intervention.  Smoking rates 
were also significantly reduced 
from baseline. 
Carson et al. (9) Before/after 
study 
n = 324 patients 
with established 
CHD or at high risk 
for CV events in a 
primary care setting 
in New York 
Pharmacist screened patient profiles 
to determine if they were candidates 
for aspirin therapy or lipid-lowering 
treatment. Recommendations for 
treatment alterations made to family 
physicians. 
Aspirin utilization in secondary 
prevention patients increased 
from 45% at baseline to 81% 
post-intervention.  LDL-C was 
significantly reduced by 26%. 
Reid et al. (13) Before and after 
study 
n = 206 patients 
with hypertension 
in the United 
Kingdom 
Blood pressure assessments and 
medication titrations by pharmacists; 
also CV risk assessments and 
cholesterol medication recommended 
to family doctor if indicated. 
Proportion of patients achieving 
target BP increased significantly 
post-clinic (from 36% at baseline 
to 85% at follow-up).  Proportion 
of patients receiving aspirin and 
statin therapy also increased 
significantly post-clinic. 
McCord (12) Before/after 
study 
n = 155 patients 
with diabetes 
Education, medication initiation or 
titration (collaborative prescribing 
agreements), monitoring by 
pharmacist. 
Significant reduction in A1c 
post-intervention (from 9.1% to 
7.49%). Significant reductions in 
LDL-C and TG were also 
observed. No significant changes 
in blood pressure. 
Geber (11) Retrospective 
chart review 
n = 146 patients 
with documented 
Pharmacist medication assessment or 
control group. 
LDL-C targets reached by 85% 
of patients in the intervention 
1
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(non-
randomized 
clinical trial) 
CAD  group vs 50% of control patients 
(p<0.01). Rates of aspirin 
utilization were not different 
between groups (97% vs 92%). 
Anaya et al. (7) Retrospective 
cohort analysis 
(before/after 
intervention) 
n = 110 patients 
with diabetes 
Disease/drug information; initiation, 
titration, and monitoring of drug 
therapy for diabetes, hypertension, 
and dyslipidemia. 
Significant reduction in A1c 
from baseline (8.9 to 8.2%). No 
significant change in cholesterol 
levels or blood pressure post-
intervention. 
DiabetesCARE 
(22) 
Before/after 
analysis 
n = 101 employees 
of the University of 
Kentucky with 
diabetes 
Group education sessions and 
individual assessments by a 
pharmacist. 
A1c was significantly reduced 
from 7.55% to 7.02% post-
intervention. Significant 
reductions in LDL, TC, and TG. 
No significant change in blood 
pressure. 
Reilly et al. (14) Before and after 
study 
n = 100 patients 
with established 
CHD in Scotland 
Medication reviews, patient 
education, ongoing monitoring of CV 
risk factors; recommendations for 
drug therapy alterations made to GP. 
Proportion of patients receiving 
aspirin increased significantly 
from 39% to 92%; proportion of 
patients achieving their SBP and 
total cholesterol targets also 
increased significantly post-
intervention. 
BP = blood pressure, CAD = coronary artery disease, CHD = coronary heart disease, HDL-C = high-density lipoprotein cholesterol, LDL-C = low-density 
lipoprotein cholesterol, SBP = systolic blood pressure, T2DM = Type 2 Diabetes Mellitus, TC = total cholesterol, TG = triglycerides 
1
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1.4 Implementation Research and CCARP II 
 
Overall, we believe sufficient evidence exists to show benefit of pharmacist-
led interventions to reduce global cardiovascular risk factors in primary care despite 
the fact that internal validity of certain studies has been inconsistent (6-16,57,66).  
However, due to the issues with the external validity of these studies as described 
above, important gaps in knowledge exist with respect to implementation of 
collaborative CV risk reduction interventions in real-world primary care settings, 
where the majority of Canadians receive their care.  For example, there is virtually 
no information available to determine the number of patients that could benefit from 
a CV risk reduction intervention because the majority of clinical intervention studies 
do not perform systematic screening, nor do they include all eligible patients due to 
the requirement for informed consent.  Thus, we aimed to conduct a project falling 
under the category of ‘implementation research’, which is translational research that 
seeks to bridge the gap between clinical science and actual clinical practice (Figure 
1.1) (67). 
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Figure 1.1: Implementation Research (67) 
 
 
We believe that real-world collaborative initiatives that target identification 
and management of CV risk factors must consist of several key characteristics.  
First, the collaborative initiative must be applicable to primary care settings.  Since 
the majority of patients in Canada receive screening, treatment, monitoring, and 
follow-up for CV risk factors from family physicians (26), it is important to develop 
collaborative initiatives that are effective and feasible in this setting.   Second, we 
believe that patients must be enrolled as a result of a systematic screening process 
for uncontrolled CV risk factors in addition to being enrolled by physician referral.  
Targeting only patients with previously recognized and documented CV risk factors 
may miss a significant proportion of individuals at risk.  Third, comprehensive CV 
risk factor reduction is important to reduce overall cardiovascular risk.  Therefore, 
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the pharmacist needs to address all risk factors including hypertension, diabetes, 
dyslipidemia, and appropriate drug utilization.  Fourth, ongoing support for patient 
adherence to drug therapy for CV risk factor reduction is important.  One study 
estimated that 50% of patients discontinue antihypertensive therapy within 6-12 
months of its initiation (68).  Similarly, it has been found that approximately half of 
patients become non-adherent to statin therapy within one year of starting (69).  
Regular patient follow-ups that include assessment of adherence and regular 
feedback regarding treatment progress are important factors in long-term adherence 
(70).  Such follow-ups are especially important when patients are first starting new 
medications and at high risk of nonadherence (69).  Finally, effective pharmacist-led 
initiatives must focus on maximizing efficiency in order to make a significant 
impact on the treatment gap in CV care.   
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CHAPTER 2 
 
2. Purpose of Project 
 
2.1 Purpose of CCARP II 
 
The purpose of our study is to implement a pharmacist-led collaboration to 
identify and manage uncontrolled CV risk factors in a family medicine setting.  We 
hope to build on the successes of previous work by our research team (CCARP) (59) 
as well as other pharmacist-led programs while addressing some of the limitations 
related to external validity as described above, specifically the setting of the 
intervention and the method of patient identification. 
 
2.2 Objectives 
2.2.1 Objective 1 
To apply a systematic screening procedure within an existing family 
medicine practice to identify patients with uncontrolled CV risk factors. 
 
2.2.1.1 Specific Aim 1 
To determine the proportion of patients at moderate or high CV risk with one 
or more uncontrolled risk factors presenting to a typical primary care clinic. 
 
2.2.1.2 Specific Aim 2 
To determine the proportion of patients at moderate or high risk for CV 
events with one or more risk factors not at target that were referred for ongoing 
pharmacist assessment and monitoring.   These patients are referred to as the 
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“enrolled patients.” 
 
2.2.1.3 Specific Aim 3 
To determine the proportion of enrolled patients with previously unidentified 
CV risk factors. 
 
2.2.2 Objective 2 
 
To reduce above-target CV risk factors in enrolled patients. 
 
 
2.2.2.1 Specific Aim 1 
 
To measure changes in blood pressure, cholesterol levels, HbA1c in the 
enrolled patients. 
 
2.2.2.2 Specific Aim 2 
 
To determine the proportion of enrolled patients who achieve a novel 
endpoint for global CV risk reduction – the Cardiovascular Risk Improvement index 
(CRI)-20 (see Endpoints, section 3.4.2.1 for description) after the intervention. 
 
2.2.2.3 Specific Aim 3 
To determine the proportion of enrolled patients who receive treatment with 
evidence-based therapies (ACEI/ARBs, beta-blockers, antiplatelet agents) before 
and after the intervention. 
 
2.2.2.4 Specific Aim 4 
To determine the proportion of enrolled patients that achieve their 
predetermined targets in CV risk factors after the intervention in CV risk factors that 
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were uncontrolled at baseline. 
 
2.2.2.5 Specific Aim 5 
To determine the proportion of enrolled patients prescribed new CV 
medications over the study period that are persistent with these new drug therapies at 
the end of the study period. 
 
2.2.3 Objective 3 
 
To evaluate the acceptability of collaborative prescribing by pharmacists in 
this setting. 
 
2.2.3.1 Specific Aim 1 
To determine the proportion of enrolled patients referred to pharmacist for 
medication initiation or titration (per collaborative prescribing agreement). 
 
2.2.3.2 Specific Aim 2 
 
To record the number of prescriptions written by the pharmacist over the 
  
study period. 
 
 
2.2.4 Objective 4 
 
To evaluate the human resource requirements of the program. 
 
 
2.2.4.1 Specific Aim 1 
 
To record all pharmacist consults and interventions to estimate the time 
required for this role. 
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2.3 Hypothesis 
 
A collaborative, pharmacist-led intervention will aid in the identification of 
patients with uncontrolled risk factors for CVD, and subsequently help reduce these 
cardiovascular risk factors to facilitate target achievement. 
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CHAPTER 3 
 
3. Methods and Procedures 
 
3.1 Clinical Intervention 
 
The clinical intervention consisted of both protocol-driven activities (i.e., 
provided in a standardized way to all patients), as well as variable activities that 
were provided in response to a patients’ clinical situation (i.e. at the pharmacist’s 
discretion).  Protocol-driven activities are important in clinical research to ensure 
high internal validity; however, a certain degree of clinical flexibility is also 
necessary to ensure external validity of professional interventions (71).  In this 
intervention, the patient screening and preparation of the CV risk assessment form 
(see description below in 3.1.1) by the pharmacist was systematic and protocol-
driven, while follow-up activities were tailored to each patient’s clinical situation. 
 
3.1.1 Patient Screening 
 
All patients who receive their primary medical care under Drs. Bettin, 
Dosman, Rajakumar, and Wu (all family physicians) at the Saskatoon Community 
Clinic were eligible for screening.  Screening was performed by the pharmacist on 
all male patients ≥ 40 years of age and female patients ≥ 50 years of age prior to a 
physician appointment for any reason.  Patients requiring screening were identified 
using HEALTHSuite, the electronic appointment scheduling software at the Clinic, 
the day prior to their physician appointment.  The pharmacist kept a master list of 
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patients already screened and compared this to the upcoming day-lists to ensure 
patients were screened only once over the study period. 
Screening involved calculation of a 10-year Framingham risk score 
(Appendix 1) (72), which requires the following patient information: Age, sex, 
blood pressure, total cholesterol, HDL cholesterol, and smoking status.  If any of 
these data were unavailable, the pharmacist notified the physician and arranged for 
the information to be collected.  Patients with a coronary risk equivalent (angina, 
revascularization procedures, acute coronary syndromes, ischemic stroke or TIA, or 
known atherosclerosis or PVD) were automatically designated as high risk (≥20% - 
10 year risk).   As per the Canadian Diabetes Association (73), all men >45 years 
and women > 50 years with diabetes were also automatically considered at high risk.  
As recommended in the 2009 Canadian Dyslipidemia Guidelines, patients with a 
family history of premature CVD (i.e. in a first-degree relative prior to 60 years of 
age) had their Framingham scores adjusted by a factor of 1.7 (women) and 2.0 (men) 
(72).  
Patients at moderate (10-19%) or high (>20%) risk of cardiovascular events 
were eligible for pharmacist follow-up if they had at least one CV risk factor not at 
guideline-recommended targets.  This included patients with hypertension and the 
last recorded chart BP > 140/90 mmHg (non-diabetics) or patients with diabetes or 
chronic kidney disease and BP > 130/80 mmHg; patients at moderate CV risk and 
LDL-C > 3.5 mmol/L or TC: HDL ratio > 5 or patients at high CV risk and LDL-C 
> 2 mmol/L or TC: HDL ratio > 4; or patients with diabetes and HbA1c > 7%.  
Cholesterol and HbA1c measurements used were the most recent values recorded in 
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the chart.  Cholesterol values measured within the year prior to screening were used; 
HbA1c levels had to be done within six months prior to screening.  If the last-
available values were older than this, these tests were reordered.  Patients did not 
receive pharmacist follow-up if they had been diagnosed with a terminal illness or 
dementia. 
Once target patients were identified, the pharmacist prepared the CV Risk 
Profile Form (Appendix 2) for the physician to review.  The CV risk profile form 
informed the physician of the patient’s 10-year CV risk, the patient’s current and 
target levels for blood pressure, cholesterol, and HbA1c, and pharmacist 
recommendations to facilitate target achievement.  Recommendations were 
primarily based on algorithms that were developed by the clinical pharmacist (E.Y.) 
and pre-approved by all participating physicians prior to commencement of the 
study.   
At the patient’s scheduled appointment with the physician that prompted the 
screening, the patient received a letter notifying them of the pharmacist’s 
involvement in their CV care (Appendix 3).  The physician reviewed the CV Risk 
Profile Form prepared by the pharmacist, assessed the patient, and implemented the 
recommendations if appropriate.  The physician then indicated on the CV Risk 
Profile Form what kind of pharmacist follow-up was required.  Follow up options 
(specific pharmacist follow up activities described below in 3.1.2) included: a) 
clinical pharmacist follow-up with all drug therapy recommendations to be 
implemented by the physician (i.e. no collaborative prescribing); b) clinical 
pharmacist follow-up with collaborative prescribing (i.e., pharmacist implemented 
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drug therapy recommendations); or c) no pharmacist follow-up.  The Cardiovascular 
Risk Profile form was then returned to the pharmacist so she could determine what 
kind of patient follow-up (if any) was needed. 
 
3.1.2 Patient Follow-up by the Pharmacist 
 
Pharmacist follow-up activities included counselling the patient on their CV 
risk and the importance of controlling risk factors, providing medication 
information, assessing and promoting medication adherence, monitoring for target 
achievement, and making additional recommendations regarding drug therapy 
changes to the patient’s physician (as needed).  To improve the efficiency of this 
intervention compared with previous, time-intensive pharmacist interventions 
(23,24,62), the intensity and frequency of patient follow-ups was determined by the 
pharmacist on a case-by-case basis by perceived need.  Patient education and 
counselling was primarily provided to patients started on new medications, as these 
are the patients at highest risk of nonadherence (69), and those with known or 
suspected adherence issues (as noted by the patient’s family physician, patient self-
report, or as suspected from the Pharmaceutical Information Program (PIP), 
Saskatchewan’s electronic prescription monitoring database).  Reminders were sent 
out to patients overdue for follow-up blood pressure or laboratory assessments 
(cholesterol or HbA1c levels).  At subsequent clinic appointments, an updated CV 
Risk Profile Form was provided to the physician along with any recommendations 
for drug therapy changes.  If urgent medication problems were identified between 
appointments (such as tolerability issues), the pharmacist discussed them with the 
patient’s physician.      
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For patients referred to the pharmacist for collaborative prescribing, the 
pharmacist was also able to initiate or adjust CV medications according to pre-
approved algorithms (see Appendices 4-10) to facilitate target achievement.  
However, due to delays in the approval of pharmacist prescribing legislation in 
Saskatchewan, collaborative prescribing was only an option for patients enrolled 
after March 4, 2011. 
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Figure 2.1: Patient Pathway 
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Complete a Framingham assessment of CV 
risk for all male patients > 40 years of age 
and all female patients > 50 years of age 
For patients at moderate or high risk of CV 
events, determine their guideline-
recommended targets for BP, cholesterol, 
and HbA1c (if applicable) 
Patients at low CV risk 
For patients not at recommended target levels for 
one or more risk factors, communicate risk factor 
information to physician, along with recommended 
medication initiation or dosage titration (per 
algorithm) 
Patients at target for all 
risk factors 
 Patient-specific medication and 
disease state counselling 
 Assessing and promoting 
medication adherence 
 Titration of medications for BP, 
cholesterol, and diabetes as required 
(per algorithm) – refer back to 
physician as required. 
 Patient-specific medication and 
disease state counselling 
 Assessing and promoting 
medication adherence 
 Assess achievement of targets 
and forward medication 
recommendations to physician as 
required. 
Patients not referred 
for pharmacist follow-
up 
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3.2 Study Duration 
 
The total study duration was 9 months.  The pharmacist began patient 
screening October 21, 2010 and continued until May 13, 2011, to ensure all patients 
had at least one month of pharmacist follow-up.  Patient follow-ups continued until 
June 17, 2011 (study end date).   
 
3.3 Ethical Considerations 
 
One of the major ethical considerations with this project related to the 
privacy of patients’ medical records, and whether they could be accessed by the 
pharmacist prior to the physician appointment to facilitate cardiovascular risk 
screening.  Several steps were taken to ensure study protocol complied with ethical 
requirements.  First of all, the investigators spoke with a privacy officer at the 
Saskatchewan Privacy Commission on three separate occasions to discuss this issue.  
Secondly, the investigators met with the Chair of Biomedical Ethics at the 
University of Saskatchewan (Dr. M. Desautels, August 2010) to discuss the project.  
Finally, the study protocol was submitted to the Biomedical Research Ethics board 
for review and approved on ethical grounds.  One of the main considerations was 
that the collaboration was to be implemented on all patients within the medical clinic 
and the pharmacist would be undertaking activities that were facilitating the care 
that was provided by the most responsible physician in every case.  We took all 
steps reasonable to inform patients about the collaborative nature of this practice and 
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offered several opportunities for patients to opt out of this collaborative approach to 
care.   
Through this process it was agreed that, as the pharmacist would join the 
practice at the Community Clinic for the duration of the study (in fact, the 
pharmacist was already employed there in advance of the project), she would 
become part of the care group and thus, a trustee of patients’ health information 
according to the Health Information Protection Act.  As a trustee, the pharmacist 
was subject to the same ethical considerations as any other healthcare professional 
(i.e. to access only information needed for a specific purpose with the reasonable 
expectation of benefiting the patient (74)). 
Due to the before/after, all-inclusive methodology of CCARP II, it was 
ultimately deemed to be a quality improvement project, and an exemption was 
granted from the Biomedical Research Ethics Board at the University of 
Saskatchewan.  Operational approval for the project was also granted from the 
Community Health Services Association at the Saskatoon Community Clinic.        
 
3.4 Endpoints 
 
Ideally, the evaluation of this clinical intervention would consider Economic, 
Clinical, and Humanistic outcomes.  Due to time constraints, however, we focused 
our analysis of the intervention on clinical endpoints, as well as a brief assessment of 
the pharmacist human resources required for the project.  Assessment of humanistic 
outcomes, such as patient and physician satisfaction, may be undertaken at a later 
date as part of a subsequent study; ethics approval for this would be sought at that 
time. 
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3.4.1 Primary Endpoint:  Patient Screening 
 
We determined the proportion of patients with uncontrolled risk factors (out 
of total number of patients screened), the number of patients with uncontrolled risk 
factors that were not previously identified, and the proportion of eligible patients 
who were enrolled and followed by the pharmacist. 
 
3.4.2 Secondary Endpoints 
 
3.4.2.1 Clinical Endpoints 
 
We determined before and after changes in clinical endpoints (SBP, LDL-C, 
TC: HDL ratio, and HbA1c) as well as the proportion of patients achieving their 
targets in each risk factor that was uncontrolled at baseline. 
We also determined the proportion of patients achieving Cardiovascular Risk 
Improvement index 20 (CRI-20):  This endpoint is achieved by all subjects who 
exhibit  20% reduction relative to target (or achievement of target) in at least one of 
SBP, LDL-C, or HbA1c, whichever risk factor(s) were uncontrolled at baseline.  
The CRI endpoint can be modified to identify greater levels of risk improvement 
(e.g. CRI-50 or CRI-75).  We also explored the proportion of patients achieving 
target thresholds for each individual CV risk factor (SBP, LDL-C, and HbA1c) as 
well as changes in these risk factors from baseline until the end of follow up.   
Appropriate utilization of antiplatelets, ACEI/ARBs, and beta-blockers in 
patients with compelling indications for these medications (according to guideline 
recommendations) was evaluated at baseline and at the end of follow up.  
Compelling indications for antiplatelet therapy were the secondary prevention of 
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established CVD, such as previous stroke/TIA/MI, angina, CABG or stent, or 
peripheral vascular disease (75).  Compelling indications for ACEI/ARB therapy 
were previous MI, heart failure with left ventricular systolic dysfunction (left 
ventricular ejection fraction (LVEF) <40%), or microalbuminuria (albumin to 
creatinine ratio (ACR) >2.0 for males or >2.8 for females on two or more 
measurements) (76,77).  Compelling indications for beta-blocker therapy were 
previous MI/stent/CABG or history of heart failure with left ventricular systolic 
dysfunction (76-78).   
Additionally, we evaluated the proportion of enrolled patients exhibiting 
primary non-adherence (defined as failure to fill a newly prescribed medication at 
all, as verified by PIP).  We also determined the proportion of patients persistent 
with new CV medications prescribed over the study period.  To be included in this 
analysis, patients must have had sufficient follow-up time on the new medication to 
warrant filling it more than once (i.e. > 68 days for regular medications and >200 
days for 100-day list drugs).  To be considered persistent with new drug therapies, 
patients’ last fill of the new medication must have occurred within 45 days prior to 
the closing date for follow-up (June 17, 2011).  For patients prescribed medications 
eligible for a 100-day fill, the drug must have been refilled within 110 days prior to 
the study close date.  This information was also obtained from PIP.     
 
 
3.4.2.2 Pharmacist Prescribing 
 
In anticipation that physicians would delegate certain patients for the 
delegated prescribing protocol, we aimed to compare the demographics of patients 
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referred to the pharmacist for medication titration versus those who were not 
referred, in addition to the proportion of referred patients who declined to participate 
in this aspect of the intervention.  We also planned to examine the clinical success of 
patients referred for prescribing by evaluating all clinical endpoints described above 
(CRI, SBP, LDL-C, TC: HDL-C, HbA1c, proportion receiving evidence-based 
therapies, etc).  We also aimed to determine the number of prescriptions written by 
the pharmacist over the study period, including new prescriptions, titrations, and 
refills.   
 
3.4.2.3 Human Resources 
 
Finally, we aimed to crudely estimate the pharmacist human resources 
required to carry out this protocol.  Thus, we recorded all pharmacist visits and 
contacts with each patient, including complete assessments (in-person), follow up 
appointments (in-person or telephone), contact with physicians or other health care 
professionals, as well as time dedicated to screening charts in preparation for 
incoming patients.   
 
3.5 Statistical Analysis 
 
Statistical analyses were conducted using SPSS version 19 for windows 
(SPSS Inc., Chicago, Ill).  Patient screening, pharmacist prescribing, and human 
resources data were descriptive.  Paired T-test was used to assess changes in clinical 
endpoints from baseline to the end of the study (LDL-C, SBP, HbA1c, TC: HDL 
ratio).  To be conservative in our estimate of the benefit of the intervention, we used 
the patient’s last observation carried forward for those that did not have repeat 
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measurements throughout the study period (79).  Chi-square was used to compare 
the proportion of patients receiving evidence-based therapies before and after the 
intervention. 
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CHAPTER 4 
 
4. Results 
 
4.1 Primary Outcome: Patient Screening 
 
Over 80 working days between October 21, 2010 and May 13, 2011, the 
pharmacist screened 566 male patients > 40 years and female patients > 50 years of 
age presenting for an appointment with one of the collaborating physicians (Figure 
4.1).  Of the 566 patients screened, 186 (32.9%) met the eligibility criteria of 
moderate or high cardiovascular risk with one or more cardiovascular risk factors 
(blood pressure, cholesterol levels, or HbA1c) above guideline-recommended target 
levels.  The remaining 380 patients screened did not meet eligibility criteria: 176 of 
these patients were at low cardiovascular risk, and the remaining 204 patients 
classified as moderate (n=119) or high (n=85) cardiovascular risk were already 
meeting guideline-recommended targets for all risk factors.   
Of the 186 patients identified as meeting the eligibility criteria, 113 (60.8%) 
were enrolled and followed by the pharmacist for the remainder of the study (see 
Figure 4.1).  Of the 73 patients not enrolled for pharmacist follow-up, 18 were 
excluded because they were deemed not to be candidates for aggressive 
cardiovascular risk reduction:  Ten of these patients had been diagnosed with 
dementia, and eight of these patients had a terminal illness.  An additional 19 of the 
186 patients identified did not arrive for their physician appointment, and thus were 
not able to be informed about the project or agree to participate.  The remaining 36 
patients out of the 186 potentially eligible were not enrolled because no pharmacist 
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follow-up was requested, either from the patient themselves or from the patient’s 
physician. 
The baseline characteristics of the 113 patients enrolled for pharmacist 
follow-up are outlined in Table 4.1.  The mean age of these patients was 66.9 years, 
and 52.2% were female.  Patients at high cardiovascular risk (those with a 
documented coronary heart disease risk equivalent or a calculated 10-year 
Framingham risk level of  > 20%) accounted for 70.8% of the patients enrolled, 
while 25.7% were at moderate cardiovascular risk (Framingham risk level of 10-
19%).  An additional four enrolled patients (3.5%) were unable to be classified 
according to cardiovascular risk level because they did not have their cholesterol 
levels measured as requested over the follow-up period.  
Of the 113 enrolled patients, 25 (22.1%) had previously diagnosed diabetes 
mellitus, 88 (77.9%) had documented hypertension, and ten patients (8.8%) had 
documented chronic kidney disease.  Four patients (3.5%) had a previous 
myocardial infarction, and six patients (5.3%) had a previous stroke or transient 
ischemic attack.  Eighteen patients (15.9%) were smokers.  Antiplatelet therapy was 
used in 28 (24.8%) of the patients enrolled, and seven patients (6.2%) were on 
anticoagulant therapy.     
At baseline, mean blood pressure of all enrolled patients was 140.3±17.6 / 
77.9±13.5 mmHg while mean LDL cholesterol (most recent measurement up to 3 
years prior to screening date) was 3.26±0.98 mmol/L.  For the 25 enrolled patients 
with diabetes, the mean HbA1c level (most recent measurement up to 6 months prior 
to screening date) was 6.68±0.61%.   
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Of the 113 enrolled patients, 48 (42.5%) had risk factors that had not been 
previously identified (had not been previously recorded in the chart).  Four of these 
patients had previously undiagnosed hypertension (and hypertension was 
subsequently diagnosed by a physician during follow-up) and 44 patients had 
previously unidentified dyslipidemia.  
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Table 4.1: Baseline Characteristics of Enrolled Patients 
 
Characteristic Measurement 
n=113 
Age – years (SD) 66.9 (11.03) 
Female Sex – No. (%) 
 
59 (52.2%) 
Current Smoker* – No. (%) 18 (15.9%) 
 
10-Year Cardiovascular Risk^ - No. (%) 
Moderate (10-19%) 
High (> 20%) 
Unable to Calculate 
 
 
29 (25.7%) 
80 (70.8%) 
4 (3.5%) 
Hypertension* - No. (%) 
 
99 (77.9%) 
Diabetes Mellitus* – No. (%) 25 (22.1%) 
 
Chronic Kidney Disease* – No. (%) 10 (8.8%) 
 
Previous Myocardial Infarction* – No. (%) 
 
4 (3.5%) 
History of CAD* – No. (%) 
 
8 (7.1%) 
Previous Stroke* – No. (%) 6 (5.3%) 
 
Antiplatelet Use* – no. (%) 28 (24.8%) 
 
Anticoagulant Use* – no (%) 7 (6.2%) 
 
Blood Pressure† – mmHg (SD) 
Systolic 
Diastolic 
 
140.3 (17.62) 
77.9 (13.5) 
Cholesterol Levels‡  – mmol/L (SD) 
Total Cholesterol 
HDL 
TG 
LDL 
Ratio (TC:HDL) 
 
5.33 (1.1) 
1.26 (0.38) 
1.87 (1.03) 
3.26 (0.98) 
4.45 (1.23) 
 
Hemoglobin A1c (diabetics)‡ – Percent (SD) 
 
6.68 (0.81) 
Duration of Follow-up – Months 
Mean (SD) 
 
4.69 (1.8) 
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Range 1 – 8.5 
^ Per Framingham Risk Score (72) 
* As documented in the patient’s chart 
† Baseline blood pressure at first physician visit following pharmacist screening  
‡ Most recent values as documented in patient chart (cholesterol level was measured at baseline or 
most recent measurement within 1 year of screening date was used; hemoglobin A1c was measured at 
baseline or the most recent measurement within 6 months prior to screening date was used). 
CAD = Coronary artery disease; HDL = High-density lipoprotein; LDL = low-density lipoprotein; 
SD = standard deviation; TG = triglycerides 
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Figure 4.1: Patient Screening Results 
 
 
*Unable to consent to participate 
n = 186 Eligible n = 380 Not Eligible 
n = 176 
Low CV Risk 
n = 204 
At all Targets 
n = 119 
Moderate CV 
Risk 
n = 85 
High CV 
Risk 
n = 73 
Not Enrolled 
n = 18 
Excluded 
n = 10 
Dementia 
n = 8 
Terminal 
Illness 
n = 19 
Did not arrive for 
physician appointment* 
n = 36 
No pharmacist 
follow-up requested 
n = 8 
Patient 
declined 
enrolment
n = 12 
Physician 
declined to 
enroll patient 
n = 16 
Unknown 
n = 113 
Enrolled 
n = 566 Screened 
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4.2 Secondary Outcomes 
 
4.2.1 Clinical Outcomes 
 
4.2.1.1 Proportion of Patients Achieving CRI 
 
The CRI-20 is achieved when a patient has achieved a minimum of 20% 
reduction in an uncontrolled risk factor relative to their target level (or achieved their 
target).  Of all the patients enrolled and followed by the pharmacist, 78 (69.0%) 
achieved the CRI-20 endpoint (Table 4.2).  Of these patients, 65.4% (51 / 78) 
achieved the CRI-20 due to reductions in SBP, 55.1% (43 / 78) due to reductions in 
LDL-C, 26.9% (21 / 78) due to reductions in the TC: HDL ratio, and 6.4% (5 / 78) 
due to reductions in HbA1c (note that patients may have had reductions in more than 
one risk factor to meet the CRI-20 criteria).  The proportion of subjects achieving 
the CRI-20 was similar among the subgroup of subjects with at least 6 months 
follow-up (70.3%), but increased to 88.1% (52 / 59) when restricting the analysis to 
patients with at least one follow-up measurement for whichever risk factor(s) were 
uncontrolled.         
The proportion of patients achieving the CRI-50 (a minimum of 50% 
reduction relative to target, or achievement of target, in at least one uncontrolled risk 
factor) was 65.5% (n=74).  CRI-50 was reached by 70.3% (n=26) of those with at 
least 6 months follow-up and by 88.1% (n=52) of those with at least 1 follow-up 
measurement (Table 4.2).      
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Table 4.2: Proportion of Patients Achieving CRI 
 
CRI Patients Number (%) 
Achieving 
Number (%) 
Not Achieving 
CRI-20 All† 
(n=109) 
78 (69.0%) 31 (27.4%) 
CRI-20 Minimum 6 months 
of follow-up 
(n=37) 
26 (70.3%) 11 (29.7%) 
CRI-20 At least one follow-
up measurement 
(n=59) 
 
52 (88.1%) 7 (11.9%) 
CRI-50 All† 
(n=109) 
74 (65.5%) 35 (30.9%) 
CRI-50 
 
Minimum 6 months 
of follow-up 
(n=37) 
26 (70.3%) 11 (29.7%) 
CRI-50 At least one follow-
up measurement 
(n=59) 
52 (88.1%) 7 (11.9%) 
*CRI refers to a minimum percentage reduction (in this case, 20% or 50%) relative to target in an 
uncontrolled risk factor from baseline.  Alternatively, CRI is considered achieved if the patient 
met their predetermined target for a risk factor that was uncontrolled at baseline.  
†An additional 4 patients (3.5%) did not have sufficient baseline data to be included in the analysis. 
 
 
4.2.1.2 Pre/Post Changes in Individual Risk Factors and Proportion of Patients 
Achieving Targets 
 
4.2.1.2.1 Systolic Blood Pressure 
 
There were 71 / 113 (62.8%) enrolled patients with baseline systolic blood 
pressure levels above their recommended target (Table 4.4).  The mean baseline 
systolic blood pressure in this patient population was 150.0 mmHg.  After the 
intervention period, the mean systolic blood pressure in this patient group was 137.3 
mmHg, a reduction of 12.7 mmHg (SD 14.5) from baseline (p=0.017).  Out of the 
71 patients with systolic blood pressures above target at baseline, 32 (45.1%) had 
achieved their target SBP by the end of the follow-up period (Table 4.5).  The 
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number of follow-up blood pressure measurements patients had throughout the study 
is listed in Table 4.3. 
 
Table 4.3: Number of Blood Pressure Measurements during Study Period 
 
n=71 patients with baseline BP above target 
Number of BP Measurements During Study 
Period 
Number (Percentage) of 
Patients 
1 (Baseline BP only) 14 (19.7%) 
2 11 (15.5%) 
3 18 (25.4%) 
4 8 (11.3%) 
5 or more (including regular home BP 
monitoring by patient) 
20 (28.2%) 
BP = blood pressure 
 
 
4.2.1.2.2 Cholesterol Levels 
 
Baseline LDL cholesterol levels were above target in 83.2% (96 / 113) 
patients enrolled.  The mean baseline LDL cholesterol in this patient population was 
3.39 mmol/L.  Following the intervention, the mean LDL cholesterol level in this 
patient group decreased to 3.03 mmol/L (p<0.001) (Table 4.4).  However, only 
29.2% (28 / 96) had achieved their target LDL cholesterol at the end of the study 
period, partially as a result of 36 patients who had no follow up test completed after 
baseline (Table 4.5).  Among the 60 patients who had a follow-up cholesterol panel 
completed during the follow up period, 26 (43.3%) had reached their target LDL-C 
levels by the end of the study period (Table 4.5).     
In total, 54 / 113 patients (47.8%) had an above-target TC: HDL ratio at 
baseline.  Mean TC: HDL ratio was reduced from 5.28 to 4.91 following the 
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intervention (p<0.001) (Table 4.4).  Of these patients, 20.4% (11 / 54) had achieved 
their target ratio by the end of the follow-up period (Table 4.5).  In contrast, TG 
levels remained essentially unchanged (mean of 1.88 mmol/L at baseline to 1.84 
mmol/L at the end of follow-up), as did HDL-cholesterol (mean of 1.25 mmol/L at 
baseline to 1.23 mmol/L at completion of follow-up).   
 
4.2.1.2.3 HbA1c 
 
There were eight diabetic patients enrolled with an elevated HbA1c at 
baseline (mean 7.51%) – see Table 4.4.  Following the intervention, the mean 
HbA1c in this patient group was reduced to 7.16%; however, this absolute reduction 
of 0.35% from baseline did not achieve statistical significance (p=0.33).  Four of 
these patients (50%) had achieved their target HbA1c by the end of the study period 
(Table 4.5).     
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Table 4.4 Pre/Post Changes in Risk Factors in Patients Above Target for Each Risk 
Factor at Baseline 
 
Parameter n Mean Pre 
+/- SD 
Mean Post 
+/- SD 
p-Value Mean Difference 
(+/- SD) 
95% CI 
Systolic 
Blood 
Pressure 
(mmHg) 
71 150.0  
+/- 12.5 
137.3 
+/- 11.6 
0.017 12.7 (+/- 14.5) 
9.22 - 16.08 
LDL-C 
(mmol/L) 
96 3.39 
+/- 0.93 
3.03 
+/- 0.96 
<0.001 0.36 (+/- 0.66) 
0.23 - 0.50 
TC: HDL 
Ratio 
54 5.28 
+/- 1.06 
4.91  
+/- 1.18 
<0.001 0.37 (+/- 0.78) 
0.16 – 0.58 
Hb A1c 
(%) 
8 7.51 
+/- 0.69 
7.16 
+/- 1.36 
0.33 0.35 (+/- 1.76) 
-1.12 – 1.82 
CI = Confidence Interval; SD = Standard Deviation 
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Table 4.5: Proportion of Patients Achieving Targets 
 
Parameter Patient 
Population 
Number (%) 
At Target at 
Baseline 
Number (%) 
Achieving 
Target 
Number (%) 
Not Achieving 
Target  
SBP All*  
(n=113) 
 
42 (37.2%) 71 (62.8%) 41 (36.3%) 
Baseline SBP 
Above Target 
(n=71) 
- 32 (45.1%) 39 (54.9%) 
Minimum of 1 
Follow-up SBP 
(n=93) 
- 62 (66.7%) 31 (33.3%) 
LDL-C All† 
(n=109) 
 
13 (11.9%) 36 (31.9%) 73 (64.6%) 
Baseline LDL-C 
Above Target 
(n=96) 
- 28 (29.2%) 68 (70.8%) 
Minimum of 1 
Follow-up LDL-
C 
(n=60) 
- 26 (43.3%) 34 (56.7%) 
TC: HDL 
Ratio 
All† 
(n=109) 
 
55 (50.5%) 62 (54.9%) 47 (41.6%) 
Baseline Ratio 
Above Target 
(n=54) 
- 11 (20.4%) 43 (79.1%) 
Minimum of 1 
Follow-up Ratio 
(n=60) 
- 36 (60.0%) 24 (40.0%) 
HbA1c All† 
(n=25) 
 
17 (68.0%) 19 (76.0%) 6 (24.0%) 
Baseline HbA1c 
Above Target 
(n=8) 
- 4 (50.0%) 4 (50.0%) 
Minimum of 1 
Follow-up 
HbA1c 
(n=13) 
- 10 (76.9%) 3 (23.1%) 
* 1 patient (0.9%) did not have sufficient baseline data to be included in the analysis 
‡ 4 patients (3.5%) did not have sufficient baseline data to be included in the analysis. 
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4.2.2 Medication Utilization 
 
4.2.2.1 Evidence-Based Therapies 
Results of pre-planned subgroup analyses focusing on patients with 
compelling indications for specific drug therapies was limited by small numbers 
(Table 4.6). 
 
Table 4.6 Utilization of Evidence-Based Therapies 
 
Drug 
Class 
No. (%) with 
Compelling 
Indication 
No. (%) 
Receiving Drug 
at Baseline 
No. (%) Receiving 
Drug at Follow-up 
Completion 
p-value 
Antiplatelet 
Therapy* 
16 
(14.2%) 
16 / 16 
(14.2%) 
16 / 16 
(14.2%) 
 
NS 
ACEI/ARB 
Therapy† 
13 
(11.5%) 
10 / 13 
(76.9%) 
 
12 / 13  
(92.3%) 
NS 
Beta-
Blocker 
Therapy‡ 
10 
(8.8%) 
8 / 10 
(80.0%) 
8 / 10 
(80.0%) 
NS 
* Compelling indications for antiplatelet therapy were secondary prevention of established CVD, 
such as previous stroke/TIA/MI, angina, CABG or stent, or peripheral vascular disease (75) 
† Compelling indications for ACEI/ARB therapy were previous MI, heart failure with left ventricular 
systolic dysfunction (LVEF <40%), or microalbuminuria (ACR >2.0 for males or >2.8 for females on 
two or more measurements) (76,77). 
‡ Compelling indications for beta-blocker therapy were previous MI/stent/CABG or history of heart 
failure with left ventricular systolic dysfunction (76-78).   
NS = not statistically significant (p>0.05). 
 
 
4.2.2.2 Changes in Medication Utilization 
Of the 71 patients with baseline blood pressures above target, 29 (40.8%) 
had a new antihypertensive medication added throughout the study period, while 15 
(21.1%) had a dosage increase of an antihypertensive they were already taking.  Of 
the 96 patients with elevated LDL-C at baseline, 14 patients (14.6%) were 
prescribed new statin medications, while an additional 17 patients (17.7%) received 
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a new cholesterol lowering agent other than a statin (ezetimibe, fenofibrate, or 
niacin) or had a dosage increase of a cholesterol medication they had been taking 
previously.  In the diabetic patients, three of the eight patients (37.5%) with elevated 
HbA1c levels at baseline were prescribed new medications, and two of these patients 
(25%) had dosage increases for antihyperglycemic medications they were already 
taking.   
 
4.2.3 Medication Adherence 
Of the 113 enrolled patients, 54 (47.8%) received a new cardiovascular 
medication or had a dose increase over the study period.  All of these patients had 
their first prescription fill within 4 weeks of the prescription being written 
(information obtained from PIP).  Thus, no patients were found to exhibit primary 
nonadherence (failure to fill a prescribed medication at least once) in this study.   
We also determined whether patients’ last fill of the new medication 
occurred within 45 days prior to the closing date for follow-up (June 17, 2011).  The 
exception to this was patients prescribed medications eligible for a 100-day fill in 
Saskatchewan – these medications must have been filled within 110 days prior to the 
study close date for the patient to be considered adherent.  Again, this information 
was obtained from PIP.  To be included in this analysis, patients must have had 
sufficient follow-up time on the new medication to warrant filling it more than once 
(i.e. > 68 days for regular medications and > 200 days for 100-day list drugs).   
Of the 41 patients receiving new medications requiring more than one fill by 
the end of the study period, 36 (87.8%) had filled the medication within the 45-day 
window prior to study closing.  Additionally, six of these patients had received more 
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than one new medication or dose increase over the study period.  All six of these 
patients met the criteria for adherence for the second medication, as did the three 
patients who had a third medication added or dose increased. 
 
4.2.4 Pharmacist Prescribing 
 
The initial study proposal had also aimed to examine several issues around 
pharmacist prescribing, such as the demographics of patients referred to the 
pharmacist for medication initiation or titration, the clinical success of patients 
receiving prescriptions from the pharmacists compared to the other patients, and the 
number of prescriptions written by the pharmacist.  However, due to unforeseen 
circumstances, the legislation allowing pharmacists to prescribe in Saskatchewan did 
not come into effect until March 4, 2011.  Thus, the majority of patients were 
already enrolled prior to this being an option.   
Of the 23 patients enrolled after March 4, 10 patients (43.5%) were referred 
to the pharmacist for ongoing medication initiation and titration as needed (i.e., 
pharmacist prescribing).  Due to the short follow-up time before the study close, 
only one prescription was written by the pharmacist (a new statin medication). The 
remaining 13 patients (56.5%) enrolled after this date were referred to the 
pharmacist for follow-up assessment but prescribing authority was not granted.  
Reasons were not provided when prescribing authority was not authorized so we 
cannot determine whether this was due to patient or physician preference. 
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4.2.5 Human Resources 
 
In total, there were 80 working days throughout the study period where the 
pharmacist actively screened patients for eligibility to enrol in the study. During this 
time, 202 hours were spent on screening activities, and a total of 566 patients were 
screened.  Thus, 2.5 hours of each working day were dedicated to patient screening, 
and each patient took a mean time of 21.4 minutes to screen. During the final month 
of the study, from May 13 until June 17, 2011, no further patients were screened or 
enrolled to ensure at least one month’s follow-up for all patients.   
The patient follow-up period ranged from October 21, 2010 (first patient 
enrolled) to June 17, 2011 (study close), and there were 97 working days within this 
timeframe.  Patient follow-ups occurred either by phone or in-person for those 
requiring blood pressure checks, blood glucose log reviews, or more in-depth 
education.  Fifteen in-person follow-up assessments were conducted by the 
pharmacist (mean duration 25 minutes) for a total of eight hours of the pharmacists’ 
time over the study period (negligible on a daily basis).  Follow-up assessments via 
telephone were the preferred method of contact for most patients.  Over the study 
period, 207 phone follow-ups were conducted by the pharmacist.  Time required for 
such assessments ranged from 5 to 20 minutes, with an average of 16.4 minutes per 
follow-up (including documentation time).  The mean amount of time each day 
devoted to phone follow-ups was 48.7 minutes. 
Additionally, tasks like pulling and reviewing patient charts took a mean of 
16.3 minutes of the pharmacist’s time on a daily basis.  Consultations with 
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physicians were a minimal contributor to the pharmacist’s time, accounting for a 
mean of 3.1 minutes daily (with a range of 1-15 minutes).    
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CHAPTER 5 
5. Discussion 
The purpose of CCARP II was to implement and evaluate a pharmacist-led 
collaboration to identify and manage uncontrolled CV risk factors in a family 
medicine setting.  In total, the pharmacist undertook CV risk screening for 566 
consecutive adult patients presenting for a physician appointment.  Of the patients 
classified as moderate or high risk for CV events, 47.7% (186/390) had one or more 
above-target risk factors (SBP, LDL-C, TC: HDL ratio, or HbA1c).  This patient 
subgroup represented 32.9% of all patients presenting for a physician appointment 
for any reason over the study period.  This confirms our hypothesis that there is still 
a need for a systematic approach to identifying patients with uncontrolled risk 
factors.  Of the patients identified, 113 (60.8%) were referred back to the pharmacist 
for ongoing monitoring and follow-up.  At the end of the study period, we found 
statistically significant reductions in SBP, LDL-C, and TC: HDL ratio in this subset 
of patients.  We also found a high rate of persistence with new medications (87.8%) 
over the follow-up period.  Thus, we believe this initial pilot implementation project 
was successful in identifying patients with uncontrolled CV risk factors, and aiding 
in the reduction of these risk factors toward target levels.  The next step would be to 
evaluate this intervention in a multi-site, randomized controlled trial to verify these 
findings. 
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5.1 Patient Screening 
 
Our screening process discovered a high rate of uncontrolled CV risk factors 
among patients visiting the clinic for any reason.  Although other pharmacist 
intervention studies have utilized screening in select patient populations, such as 
diabetes (15), CAD (14), or hypertension (13), this is the first study to our 
knowledge that incorporates systematic screening for CV risk factors in all patients 
presenting to a family medicine clinic.  An important strength of this approach was 
that patients were screened prior to a physician appointment for any reason; thus, 
even patients who are not diligent about seeing their physician for regular preventive 
care were screened (39).  Furthermore, physicians were provided with the relevant 
information at the time of an existing appointment so appropriate decisions could be 
made without delay.   
This method of screening was useful for identifying patients with above-
target CV risk factors, as well as for generating referrals for pharmacist assessment 
and follow-up.  Although literature suggests that the management of CV risk factors 
has been improving over the last couple decades (27,35), our study showed that the 
presence of uncontrolled CV risk factors is still quite common.  The first CCARP 
study, which relied on physicians to identify and refer patients for the pharmacist, 
resulted in a slow accrual of patients despite broader inclusion criteria and a longer 
period of patient enrolment (59).   In this project, we could ensure a systematic 
process was used to identify patients.  This illustrates the importance of proactive 
screening for pharmacist interventions, rather than relying on referrals to identify 
patients (59).   
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Of the 186 moderate to high risk patients with one or more risk factors above 
target, 113 (60.8%) were referred back to the pharmacist for ongoing follow-up.  Of 
those patients not referred, 18 were excluded due to pre-existing dementia or a 
terminal illness, and therefore were not suitable candidates for aggressive CV risk 
reduction.  An additional 19 patients did not arrive for their physician appointment, 
and were thus not able to be notified of the pharmacists’ involvement in their care 
and were not able to be followed-up for ethical reasons.  Excluding these patients 
increases the physician referral rate to over 75%, suggesting physicians were 
generally supportive of this collaborative intervention.  Although a specific 
physician follow-up survey would have confirmed this inference, it was not part of 
the a-priori objectives of this project for practical reasons.  The remaining 36 
patients were not referred for pharmacist follow-up either at their request (8 patients) 
or due to the preference of their physician (12 patients); for the remaining 16 
patients no reason was provided.  
We believe the rate of uncontrolled risk factors may actually be higher in 
other primary care settings in Saskatchewan.  The clinic where this intervention was 
implemented had already undertaken initiatives intended to improve chronic disease 
management among their patients.  First, physicians employed by this clinic were 
paid by salary rather than fee-for-service.  As outlined in the Action Plan for 
Primary Care (42), this payment structure is considered to be more appropriate to 
achieve optimal care of patients with chronic diseases.  Also, this medical clinic had 
participated in Saskatchewan’s Health Quality Council Chronic Disease 
Management Collaborative, a quality improvement initiative to improve care for 
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patients with established CAD or diabetes.  Approximately 25% of family 
physicians in Saskatchewan were involved in this initiative (80).  Notably, we 
identified very few patients with existing CAD or diabetes and at least one 
uncontrolled risk factor, suggesting these initiatives were successful in facilitating 
monitoring and follow-up of patients with these conditions.  Despite the existence of 
these quality improvement systems, our intervention appeared to provide additional 
benefits to the overall control of CV risk among clinic patients.   
Patient screening consumed approximately 70 minutes per eligible patient 
identified.  This screening estimate takes into account that approximately 4 patients 
needed to be screened to identify one eligible patient.  Included in the screening time 
estimate was also the time required to review upcoming appointment lists and 
confirm the patient had not been screened previously.  Additionally, the time 
required to complete the CV risk profile form and formulate recommendations was 
also included in the time estimate for screening activities.  One potential contributor 
to the time required for screening was the paper charting system employed by the 
clinic.  Implementation of electronic health records would have undoubtedly 
streamlined the screening process.  Also, it is possible that other staff members, such 
as clinical office assistants, could have carried out certain elements of the screening 
process.  In this way, the charts of uncontrolled patients could be flagged for the 
pharmacist to review and provide recommendations to the physician.  However, 
many clinics likely do not have the extra staff in place to do this, which is a gap that 
pharmacists could potentially fill in these settings. 
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5.2 Impact of the Study Design 
 
The key advantage of our non-randomized, before - after study design was 
that all eligible patients could be included and managed under real-world conditions. 
The inclusive nature of this study design enhances the generalizability of our results 
to real-world practice settings, which was an important goal of CCARP II.  
Previously, our research group studied a similar pharmacist intervention with a RCT 
design (59).  However, screening for patient recruitment was far slower due to the 
requirements for physician referral and patient consent.  Additionally, this real-
world design allowed us to avoid the potential for contamination, when physicians 
are treating patients in both the intervention and the control group in a single-site 
study (59).   
The main disadvantage of the current study design was the lack of a 
concurrent control group.  As a result, it is difficult to determine the extent to which 
‘regression to the mean’ may have influenced the before-after changes in clinical 
outcomes observed.  Regression to the mean refers to the fact that extreme values of 
a given variable tend to be closer to the population average on repeat measurement, 
even without intervention (81).  As a result, the secondary analyses that examined 
before-after changes in clinical CV risk factors should be interpreted with caution.  
However, systematic screening of patients for uncontrolled CV risk factors 
uncovered many patients that may not have been detected without the support of this 
collaborative protocol.  
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5.3 Clinical Outcomes 
 
The majority of the patients enrolled for ongoing pharmacist follow-up in 
this study were at high CV risk (70.8%), as calculated by the Framingham risk score 
(72); however a relatively low proportion had a history of CAD or stroke (12.4%).  
The low proportion of patients with established CAD and above-target risk factor(s) 
is likely due to the Clinic’s participation in the Health Quality Council Chronic 
Disease Management Collaborative, which promotes regular screening and follow-
up of CV risk factors in patients with established CAD.  Additionally, the proportion 
of diabetic patients with above-target risk factors identified was also quite low 
(22.1%), which is again likely due to the regular monitoring and follow-up these 
patients receive as part of the Collaborative.  Thus, the intervention appeared to be 
most useful for identifying primary prevention patients at high risk for CV events.  
From a population perspective, the majority of CV events occur in patients 
considered as primary prevention (41) so identifying high risk, primary prevention 
patients in addition to those receiving secondary preventative care would appear to 
be a good strategy to address CV morbidity in a primary care clinic.  The most 
common above-target CV risk factor identified in this study was LDL-C (83.2%) 
followed by SBP in 62.8% of the patients enrolled.   
 
5.3.1 Systolic Blood Pressure 
 
There was a significant reduction in SBP in patients with above-target SBP 
at baseline (-12.7 mmHg, p=0.017) over the follow-up period.  Additionally, almost 
half of the patients (45.1%) with above-target SBP at baseline had achieved their 
target by the end of the follow-up period.  New antihypertensive medications were 
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started during the follow up period in 40.8% of these patients, with an additional 
21.1% receiving an increased dose of an antihypertensive they were already taking.  
The majority of these patients (64.8%) had two or more follow-up blood pressure 
assessments over the study period.  
The magnitude of SBP reduction observed here is similar to what has been 
reported in previous pharmacist intervention studies to reduce global CV risk 
(8,10,15,57).  Bunting and colleagues conducted a before/after analysis of a multi-
pharmacist, multi-site medication therapy management program for hypertension 
and diabetes, and found a mean reduction in SBP of 11mmHg (8).  Clifford and 
colleagues conducted a randomized controlled trial of a pharmacist intervention to 
reduce vascular risk in patients with diabetes.  They found a significant 14mmHg 
reduction in SBP in the pharmaceutical care group after the intervention, and a 
7mmHg reduction in the control group (10).  Simpson and colleagues found a 
statistically significant reduction in SBP of 7.4mmHg in the intervention group but a 
non-significant reduction of 2.5mmHg in the control group in a randomized 
controlled trial of pharmacists’ interventions on diabetes patients in primary care 
(15).  In the study by Rothman and colleagues, patients in the pharmacist 
intervention group had a 7mmHg reduction in SBP while patients in the control 
group had a 2mmHg increase in SBP (p=0.008 for the difference) (57).  Thus, in 
studies that had a concurrent control group, the change in SBP in these patients 
ranged from -7mmHg to 2mmHg; this provides a crude estimate of the impact 
regression to the mean may have had on our observed SBP reductions.    
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In our study, there was no standardized assessment of BP because of 
practical constraints on time and resources.  As a result, the BP that was recorded in 
the patients’ charts was used.  This may be susceptible to errors in how or when 
blood pressure was measured, which could potentially affect these results.  
However, this is a limitation faced by clinicians making decisions in real-world 
clinical practice as well.       
 
5.3.2 Cholesterol Levels 
 
We also observed statistically significant reductions in LDL-C (0.36 
mmol/L) and the total cholesterol: HDL ratio (0.37) over the study period, with 
29.2% and 20.4% of patients achieving their targets, respectively.  These reductions 
were similar, although slightly less marked than what has been reported in other 
studies; Al Mazroui and colleagues had an LDL-C reduction of 0.44 mmol/L in the 
intervention group after 4 months of follow-up (6), Bunting and colleagues found a 
0.41 mmol/L reduction in LDL-C after one year of follow-up (8), and Johnson and 
colleagues found a 0.44 mmol/L reduction in LDL-C after one year of follow-up 
(22).  Several other pharmacist intervention studies (15,57,59) did not show a 
statistically significant impact on lipid levels.  In comparative studies, changes in 
LDL-C among patients allocated to control groups have ranged from +0.03 mmol/L 
to -0.24 mmol/L (6,17,25). 
Our ability to assess changes in cholesterol levels was limited by the short 
duration of follow-up.  In keeping with the real-world nature of CCARP II, 
laboratory assessments were ordered at the discretion of the participating physicians 
as clinically indicated during the study period; we did not obtain true baseline and 
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follow-up cholesterol panels for all patients.  If the patient had had a cholesterol 
panel done within the last year, this was used as their baseline; if not, a baseline 
cholesterol test was recommended.  Many patients (n=36) did not have both baseline 
and follow-up cholesterol panels done over the study period, so a baseline-
observation-carried-forward (BOCF) approach was used in these patients (79).  
Despite the conservative nature of our analysis, however, a beneficial effect of the 
intervention was still observed on cholesterol levels. 
Another potential reason for the low proportion of patients achieving their 
cholesterol targets post-intervention was an apparent reluctance to start statin 
therapy.  Of the 96 patients with above-target LDL-C at baseline, only 14 (14.6%) 
received new statin prescriptions over the study period, while another 17 patients 
received other cholesterol-lowering agents or had a dosage increase in cholesterol 
medications they were already taking (including statins).  An additional 27 patients 
with above-target LDL-C at baseline (28.1%) were recommended to start statin 
therapy, and either refused (12 patients) or wanted additional time to implement 
lifestyle changes first (15 patients).  A longer-term intervention would be required to 
determine if greater improvements could be achieved in this subgroup of at-risk 
patients.   
 
5.3.3 HbA1c 
 
Overall, a small number (n=8) of the diabetic patients enrolled had above-
target HbA1c at baseline.  Although the reduction in HbA1c from baseline in this 
subset of patients did not reach statistical significance, 50% of these patients 
achieved their HbA1c target at the end of the study period.          
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5.3.4 CRI 
 
Although CV risk factors tend to cluster within individual patients, there are 
few measures in the literature that capture improvements in CV risk from a global 
perspective.  The Framingham Risk Score has been used to measure global CV risk 
change in previous studies (82); however, it only been validated in primary-
prevention populations, it is not sensitive to small changes, and it does not register 
changes in HbA1c, a clinical endpoint that was of interest in our study.      
Our research group has developed a new global CV risk endpoint, the CRI 
(Cardiovascular Risk Improvement index). The CRI is a binomial outcome that 
indicates a minimum reduction (relative to target), or achievement of target, in any 
risk factor (SBP, LDL-C, or HbA1c) that was uncontrolled at baseline.  Thus, the 
CRI-20 refers to a minimum of 20% reduction relative to target, and the CRI-50 
refers to a minimum of 50% reduction relative to target.  We found that the majority 
of patients achieved both the CRI-20 (69.0%) and the CRI-50 (65.5%), indicating 
good progress towards achievement of CV risk reduction targets in an intention to 
treat analysis.  Furthermore, when the analysis was restricted to those patients who 
completed at least one follow-up measurement of the target risk factor, 88.1% of 
patients achieved both the CRI-20 and the CRI-50.  Again, a longer-term 
intervention would be required to determine if these initial improvements could be 
sustained.     
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5.4 Medication Adherence/Persistence 
 
Primary non-adherence, where individuals fail to obtain the first prescription, 
has been reported in other clinical settings (83,84).  However, all 54 patients who 
received new medications or had dosage increases over the study period had the 
medication filled for the first time within 4 weeks of the prescription being written.  
We also found a high rate of medication persistence in patients prescribed new 
medications requiring more than one fill before the end of the study period; 36/41 
patients (87.8%) had refilled the medication within a 45-day window prior to the 
study end date.  The short duration of follow-up for our study limited our ability to 
assess long-term adherence with new therapies; however, our results demonstrate a 
promising rate of early persistence and primary adherence with new medications 
started over the study period in a subgroup of patients considered at the highest risk 
(new-users) (69).    
The Pharmaceutical Information Program (PIP) was used to assess 
medication adherence and persistence in this study.  The main limitation to using 
administrative databases such as PIP to assess adherence is that these databases 
provide information on refill adherence, rather than actual medication consumption 
by the patient (85,86).  However, studies have found a high rate of concordance 
between prescription claims data and pill counts (85), and suggest that 
administrative databases are a convenient, objective, and inexpensive way to assess 
medication adherence in health services research (86).  Additionally, patient-
reported adherence measures may overestimate adherence rates if they are the sole 
method used (87).  
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5.5 Pharmacist Prescribing 
The legislation permitting collaborative prescribing by pharmacists in 
Saskatchewan did not come into effect until March 4, 2011, by which time the 
majority of patients had already been enrolled in our study.  Thus, our ability to 
assess the utility of collaborative prescribing by the pharmacist was limited because 
our intervention was scheduled to be completed by June 2011.  Despite the short 
time available to evaluate this tool, the preliminary data from our study suggest this 
strategy was well accepted by collaborating physicians.  Of the 23 patients referred 
after pharmacist prescribing was an option, 10 (43.5%) were referred for this 
service.  The only other study to examine this issue was conducted by Anaya and 
colleagues; they found that 110/579 patients (19.0%) were referred for collaborative 
prescribing by the pharmacist in an outpatient diabetes management clinic (7).  
However, only one prescription was written by the pharmacist over the study period, 
due in part to the short duration of follow-up for these patients.   
The perceived acceptability of this option among physicians may be partially 
explainable by the steps we undertook prior to the beginning of the study.  First, we 
consulted with each participating physician to provide input on the proposition for a 
collaborative prescribing agreement.  Second, we developed prescribing algorithms 
on the basis of Canadian guidelines and obtained input from collaborating 
physicians so they were precisely aware how the management would be undertaken 
by the pharmacist (Appendices 4-10).  Finally, we ensured that the decision to 
delegate prescribing for each patient was made by physicians on a case-by-case 
basis, so they could maintain control of the overall management of each patient’s 
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care.  We believe these steps helped to develop a true collaborative partnership.    
However, it should be noted that our study involved a select group of physicians 
who opted to participate in a collaborative initiative with a pharmacist; thus, these 
results may not be generalizable to all physicians.  Further study on this issue is 
warranted.    
 
5.6 Human Resources 
A single pharmacist, working with four salaried family physicians, 
undertook the CCARP II intervention.  Collectively, the four physicians involved 
with the project provided approximately 2.5 full-time equivalents of direct patient 
care.  Routine physician appointments are booked for 15 minutes at this clinic.   
Patient screening activities took approximately 2.5 hours of the pharmacist’s 
time on a daily basis.  As discussed previously, it may be possible to improve the 
efficiency of the screening procedures using electronic health records.  Patient 
follow-up activities took approximately 65 minutes of the pharmacist’s time on a 
daily basis, with just over 48 minutes daily devoted to telephone follow-ups with 
patients and just over 16 minutes daily spent reviewing charts for updated 
information.   
 Routine patient follow-ups were generally conducted by phone.  In-person 
assessments by the pharmacist were reserved for patients requiring blood pressure 
checks or review of blood glucose logs for collaborative prescribing purposes, or 
those patients with more in-depth education needs (patients with known or suspected 
poor adherence, language barriers, or those requesting more information).  The use 
of phone follow-ups for most routine issues helped enhance the efficiency of the 
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intervention; average time spent on phone follow-ups was 16.4 minutes, as 
compared to an average of 25 minutes when patients were seen in-person.  If 
pharmacist prescribing had been an option earlier in the study, that may have 
increased the amount of time the pharmacist spent on in-person follow-up 
assessments.  However, it is not clear if additional benefits to CV risk factors would 
have been achieved. 
Time spent on patient follow-up assessments in other similar pharmacist 
interventions, when reported, has ranged from 15-60 minutes (6,8,10,12,14,16,23), 
with 30-minutes follow-up appointments being the most common (8,12,14,16).  
Some studies had pre-specified intervals for patient follow-ups (10,24,25,59), while 
others had flexible follow-up schedules, tailored to the patient’s needs at the 
discretion of the pharmacist (6-8,15).  In our intervention, follow up visits were not 
protocol-driven.  The pharmacist aimed to target patients at greatest need for 
ongoing support and triage their time appropriately.  Although this approach is 
considered more difficult to quantify, we believe it is the most practical approach to 
a professional intervention that will be conducted in real-world settings (71).           
 
5.7 CCARP II Intervention 
Overall, the duration of the CCARP II initiative was quite short (8.5 months) 
with no lead-in time for the pharmacist before the start of the study.  Previous 
reports suggest that it may take approximately four months before pharmacists 
become comfortable with their role on a healthcare team and develop the necessary 
collaborative relationships (88,89).  Despite the fact that no lead-in time was 
possible due to time constraints for CCARP II, we still found a benefit to the 
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collaborative intervention.  Additionally, the physicians involved in the project did 
not have experience working with clinical pharmacists in this setting.  Again, we 
believe our clearly defined roles and responsibilities that were mutually agreed upon 
with collaborating physicians from the beginning facilitated a relatively smooth 
transition to collaborative care.  
CCARP II involved a combination of protocol-driven activities and activities 
that were tailored to the patients’ clinical situations at the discretion of the 
pharmacist.  The patient screening activities and documentation/recommendation 
procedures were consistently protocol-driven (provided in the same way to every 
patient), thus enhancing the internal validity and the reproducibility of our study 
(71).  However, to ensure our study would also be applicable and feasible in a real-
world clinical practice (71), patient follow-up activities were tailored to each 
patient’s clinical situation, rather than using a standardized follow-up protocol for all 
patients (10,24,25).  The use of protocol-driven clinical activities in a research study 
to ensure internal validity versus the need for clinical judgment to ensure external 
validity is a common dilemma in clinical research (71).   
Pharmacist follow-up activities included patient counseling on 
cardiovascular risk and/or medications, promoting adherence to drug therapy or 
lifestyle changes, monitoring for target achievement, and making recommendations 
to physicians to facilitate target achievement.  Thus, clinical judgment by the 
pharmacist was required to determine how best to follow-up with each patient.  This 
flexibility in follow-up activities allowed for more efficient patient follow-ups 
(average of 16 minutes) compared with some studies using more structured 
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appointment-based follow-ups (8,12,14,16,17).  However, this does slightly limit the 
reproducibility of the follow-up portion of this intervention.   
 
5.8 Remaining Questions 
 
There are a few remaining limitations of our initiative that warrant further 
discussion.  First of all, the pharmacist was not able to follow-up with patients with 
uncontrolled risk factors who did not present for their scheduled physician 
appointment.  This was due to ethical constraints of the study; because these patients 
were not able to be informed of the pharmacist’s role in their care at their doctor 
appointment, the pharmacist was not able to contact these patients to follow-up.  
This is unfortunate, because this is a pool of patients that could potentially benefit 
from more persistent follow-up to ensure their cardiovascular risk factors are 
addressed (especially if these patients frequently miss medical appointments).  
Although the mean age of the patients not arriving for their appointment (62 years) 
was similar to those enrolled, as was the proportion with hypertension (75%), a 
higher proportion of these patients had diabetes (40%) compared to the patients that 
were enrolled (22.1%).  Additionally, 83% of the patients with diabetes who did not 
arrive for their physician appointment had above-target HbA1c levels, compared 
with 32% of the diabetic patients that were enrolled for pharmacist follow-up, 
suggesting that these patients were not adherent with their regular physician follow-
ups for diabetes every three months, as was the standard at the Clinic since 
participating in the Health Quality Council Chronic Disease Management 
Collaborative.    
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CCARP II was a single-centre pilot study conducted by a single pharmacist 
working with four family physicians who volunteered to participate in the project; 
this may limit the generalizability of our findings.  Additionally, this initiative was 
conducted in a family medicine clinic with salaried family physicians; this may limit 
the generalizability of our findings to settings where physicians are paid on a fee-
for-service basis.  These issues warrant further study, preferably in a multi-center, 
randomized clinical trial involving several pharmacists.  In addition, the primary 
investigator had to serve all major roles to carry out this study.  She served as the 
clinical pharmacist, collected all data, and analyzed / synthesized all results.  Ideally, 
these roles would have been performed by different, blinded individuals to minimize 
the risk of bias.     
 Due to time constraints with our study, we were not able to formally evaluate 
physician and patient satisfaction with this initiative.  Such an evaluation would help 
give a more complete picture of the benefits and areas for improvement with the 
intervention, and will be conducted in the future as part of a separate study.  
However, similar studies suggest that physician and patient satisfaction are generally 
very high with these types of interventions (13,22,57,90,91).  Anecdotally, 
physicians and patients in the clinic appeared very supportive and accepting of this 
new collaborative program. 
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CHAPTER 6  
6. Conclusions and Perspectives 
Despite improvements in CV risk factor identification and management over 
the last two decades (27,35), CCARP II showed that there are still opportunities for 
pharmacists to contribute to the care of patients with CVD or its risk factors.  We 
found that approximately one third of adults presenting for a family physician 
appointment were at moderate or high risk of cardiovascular events and had at least 
one risk factor above guideline-recommended targets.  Thus, it would appear that a 
systematic screening procedure is necessary to ensure CV risk management is 
consistently applied to all clinic patients.  We also found significant reductions in 
SBP, LDL-C, and TC: HDL ratio in patients monitored and followed-up by the 
pharmacist on an ongoing basis.  A high rate of persistence to new medications 
(87.7%) was observed in patients receiving pharmacist follow-up. 
Two key aspects of the CCARP II intervention were the systematic approach 
to patient screening and identification, and the real-world, family medicine setting in 
which it was implemented.  Further study is warranted to determine if the benefits 
observed in our pilot study can be reproduced with a multi-center, randomized 
controlled trial involving multiple pharmacists.   
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CHAPTER 8 
 
8.  Appendices 
 
Appendix 1: Framingham Calculator for Estimating Cardiovascular Risk (71) 
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Appendix 2: Cardiovascular Risk Profile Form 
 
Cardiovascular Risk Profile 
 
Completed by Erin Yakiwchuk: ____________     For Dr. ____________ 
 
Gender:   M   F     DOB:  ___________ 
 
Smoking Status:   Non-smoker    Ex-smoker    Current smoker (__________) 
 
Estimated 10-Year Cardiovascular Risk:  Moderate (10-20%)     High (>20%) 
 
 Obtained from:  Framingham    CHD Risk Equivalent:  ___________________ 
  
 
Diabetes:   Yes     No       Chronic Kidney Disease:   Yes     No     Antiplatelet: 
___________ 
 
 
Current Blood Pressure (                 ):  _____________    Target Blood Pressure:  ________ 
 
Hypertension Meds: 
 
 
Cholesterol Levels (                 )   
 TC: ________ 
 TG: ________ 
 HDL: _______    Target LDL:  ________ 
 LDL: _______    
        TC: HDL: _______           Target TC: HDL (Ratio):  ________ 
 
Cholesterol Meds: 
 
 
If Diabetic:  HbA1c (               ): ______________ Target A1c  < 7% 
     (A1c may be modified if high risk for hypoglycemia) 
Diabetes Meds: 
 
 
Pharmacist Recommendations:   
 
 
 
 
 
 
Pharmacist to follow-up with patient? – PHYSICIAN TO SPECIFY:  
 
 
 
 
 
 
Appendix 3: Letter to Patients 
 
     To provide medication and disease-state counseling, assess and promote adherence, and monitor for 
target achievement.  All recommendations for drug therapy changes to be forwarded to physician. 
 
     As above AND independently titrate medication(s) to achieve specified CV risk factor target(s) per 
algorithm. 
 
     No patient follow-up required               
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Appendix 3 : Letter to Patients 
 
 
 
Dear Patients, 
 
 
I would like to inform you about a new member of the team at the Community 
Clinic, Erin Yakiwchuk.  Erin is a licensed pharmacist who will be helping me look 
after your medications and risk factors for heart disease. 
 
Part of her job will be to keep track of your blood pressure, cholesterol, and blood 
sugar on a regular basis by checking the results of your tests and updating me if your 
medications need to be reviewed.     
 
If you have any questions or concerns about Erin’s role at the clinic, you can talk to 
me during today’s appointment or you can speak to Erin directly by calling the 
Community Clinic Pharmacy at 664-4277.   
 
 
Sincerely, 
 
 
Dr. __________ 
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Appendix 4: Algorithm for Uncomplicated Hypertension 
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Appendix 5: Algorithm for Patients with Hypertension and Diabetes 
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Appendix 6: Algorithm for Hypertension and Coronary Artery Disease 
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Appendix 7: Algorithm for Hypertension in Heart Failure 
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Appendix 8: Cholesterol Algorithm for Moderate Cardiovascular Risk 
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Appendix 9: Cholesterol Algorithm for High Cardiovascular Risk 
 
 
 
 
 
 
 
 
 
 
 
  
92 
Appendix 10: Diabetes Algorithms 
 
 
 
 
Jone = Jone Barry, Nurse Practitioner at the Community Clinic who initiates new patients on insulin 
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